Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010

Breast Cancer Research and Treatment

Volumn 137, Issue 1, 2013, Pages 285-296

  Dusetzina, Stacie B ^a   Alexander, G Caleb ^b,c   Freedman, Rachel A ^d   Huskamp, Haiden A ^e   Keating, Nancy L ^e,f  

^a IL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CYP2D6; Drug interaction; Drug utilization; FDA advisories; Tamoxifen

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6 INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; TREND STUDY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DEPRESSION; DRUG INTERACTIONS; DRUG LABELING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TAMOXIFEN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871792899     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2330-z     Document Type: Article

References (45)

1. Breast cancer key statistics. http://www.cancer.org/Cancer/BreastCancer/ DetailedGuide/breast-cancer-key-statistics. Accessed 10 April 2012
2. Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103(18):1397-1402
3. Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76(1):27-36
4. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236
5. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784-3796
6. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, version 2.2011. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed 10 April 2012
7. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619-629
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
9. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23(36):9312-9318
10. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J Am Med Assoc 302(13):1429-1436
11. Desmarais JE, Looper KJ (2009) Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70(12):1688-1697
12. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30-39
13. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758-1764
14. Stearns V, Rae JM (2008) Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 10:e34
15. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61-74
16. CDER 2006 Advisory Committee Meeting Documents. http://www.fda.gov/ohrms/ dockets/ac/cder06.html. Accessed 10 April 2012
17. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122(3):609-617
18. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104(6):441-451
19. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(6):452-460
20. Hertz DL, McLeod HL, Irvin WJ Jr (2012) Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17(5):620-630
21. Ferraldeschi R, Howell SJ, Thompson AM, Newman WG (2010) Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol 28(29):e584-e585;author reply e586
22. Gelenberg A, Freeman M, Markowitz J, Rosenbaum J, Thase M, Trivedi M, Van Rhoads R, Reus V, DePaulo J Jr, Fawcett J et al (2010) Practice guideline for the treatment of patients with major depressive disorder, 3rd edn. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Washington, DC
23. Higgins MJ, Stearns V (2010) CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep 12(1):7-15
24. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28(16):2768-2776
25. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M (2008) Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 165(10):1251-1255
26. Desmarais JE, Looper KJ (2010) Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas 67(4):296-308
27. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J (2008) Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 30(2):112-126
28. Hunter MS, Grunfeld EA, Mittal S, Sikka P, Ramirez AJ, Fentiman I, Hamed H (2004) Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology 13(11):769-778
29. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJ, Goodwin RD, Kubzansky L, Lydiard RB, Massie MJ, Katon W, Laden SK et al (2008) Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 30(3):208-225
30. Cubanski J, Neuman T, Damico A, Huang J (2009) Examining sources of supplemental insurance and prescription drug coverage among Medicare beneficiaries: findings from the Medicare current beneficiary survey, 2007. The Henry J. Kaiser Family Foundation, Menlo Park
31. Thompson Reuters: comparative effectiveness research - research and analytics. http://thomsonreuters.com/products-services/healthcare/healthcare- products/a-z/comparative-effectiveness-research/. Accessed 10 April 2012
32. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258-1267
33. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154(9):854-864
34. Farley JF, Harley CR, Devine JW (2006) A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care 12(2):110-119
35. Parsons LS (2001) Reducing bias in propensity score matched-pair sample using greedy matching techniques. In: Poster presented at the twenty-sixth annual SAS users group international conference, 22-25 April 2001, Long Beach, CA
36. Kelly CM, Pritchard KI (2012) CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst 104(6):427-428
37. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104(16):1264
38. Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(16):1263-1264
39. Stanton V Jr (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104(16):1265-1266
40. Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107(2):167-180
41. Goodwin JS, Zhang DD, Ostir GV (2004) Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc 52(1):106-111
42. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A (2000) Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356(9238):1326-1327
43. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T et al (2011) Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 155(11):772-785
44. Gartlehner G, Hansen RA, Reichenpfader U, Kaminski A, Kien C, Strobelberger M, Van Noord M, Thieda P, Thaler K, Gaynes B (2011) Drug class review: second-generation antidepressants: final update 5 report. Oregon Health & Science University, Portland
45. Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ (2010) Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 28(35):5147-5152